Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neoprobe

This article was originally published in The Gray Sheet

Executive Summary

Developer of the RIGS cancer detection system announces that its registration statement for a selfunderwritten public offering of 2 mil. shares was declared effective Sept. 30 by the Securities and Exchange Commission. Dublin, Ohio-based Neoprobe originally filed a registration statement for an offering of 2.9 mil. shares to be underwritten by D. Blech & Co. ("The Gray Sheet" Aug. 22, p. 6). However, in the wake of the Sept. 22 temporary closing of D. Blech & Co. for its failure to comply with SEC minimum requirements for net-capital, Neoprobe opted to self-underwrite its offering. The firm will receive gross proceeds of about $4.3 mil., compared to the $9.3 it expected to net from the D. Blech-underwritten offering. The company says it still plans to use about 70% of the proceeds to fund further research and development of the RIGS system

You may also be interested in...



Breckenridge Eyes First Kyprolis Generic With FDA Approval

Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.

Nestlé Sees Importance Of Local Brands In ‘Fragmented’ VMS Market

As Nestlé continues to expand its presence in the VMS market it will not take a brand popular in one country and “force” that name on consumers in a different part of the world, says CEO Mark Schneider.

Lupin Gets Another First With Fostair

Lupin has claimed a first with a UK approval for a rival to Fostair. The Indian company has told Generics Bulletin that it is planning to roll out the Luforbec branded generic later this year.

UsernamePublicRestriction

Register

MT002920

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel